Navigation Links
Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy

Results from the first clinical trial of a therapeutic cancer vaccine combining the synthetic bacterial DNA sequence, CpG 7909 (ProMuneTM, Coley Pharmaceutical), with a peptide antigen were reported today in the Journal of Clinical Investigation. The paper shows that the CpG 7909 DNA sequence is safe, and increases the immune system's ability to recognize and destroy cancer cells. The Phase I study was conducted by the Lausanne Branch of the Ludwig Institute for Cancer Research (LICR) at the Lausanne University Hospital in Switzerland, in the framework of the international Cancer Vaccine Collaborative (CVC), a partnership established by the New York-based Cancer Research Institute (CRI) and the LICR.

"What we're doing is testing a novel adjuvant, a compound that stimulates the immunological response to a vaccine, which is essentially tricking the immune system into thinking the vaccine is a bacterial infection," says lead author Dr. Daniel Speiser from the LICR Lausanne Branch. "The immune system mounts a response against the peptide antigen, the cancer-specific target, in the vaccine, and thus also against the antigen on the cancer cells."

The vaccine, combining the CpG 7909 adjuvant and Incomplete Freund's Adjuvant (IFA) with a synthetic peptide (protein fragment) from a melanoma antigen known as Melan-A/MART-1, induced CD8+ T cells that specifically recognized cells displaying Melan-A/MART-1 on their surface. This T cell response occurred in all eight patients in the trial. Responses were one order of magnitude higher than those observed in eight patients who received the Melan-A/MART-1 antigen with IFA but without CpG 7909 in previous studies.

According to Dr. Jill O'Donnell-Tormey, the Executive Director of CRI, the trial is part of the CVC's systematic, coordinated vaccine development approach that compares single vaccine variables in parallel. "We've identified many cancer antigens, and the challenge is to determine which cancer vaccine
'"/>

Source:Ludwig Institute For Cancer Research


Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. EuroVacc 02 HIV Vaccine Trial Begins
8. Active Vaccine Prevents Mice From Developing Prion Disease
9. New Vaccine To Be Used For First Time In Polio Outbreak Response
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pathogen Mimicking Vaccine Strategy For Cancer Therapy

(Date:4/18/2014)... crystallography and nuclear magnetic resonance imaging (NMR) to gain ... such efforts have long been hampered by the fact ... and often in ordered and crystalized form to be ... into the structure of most molecules. , Harvard researchers, ... of the past. , A team of scientists, ...
(Date:4/18/2014)... the past 20 years, researchers have published soil organic ... have suggested that soil organic carbon can be sequestered ... to no-till systems. However, there is a growing body ... and soybean rotations without cover crops, small grains, and ... at the published rates. , "Some studies have shown ...
(Date:4/18/2014)... Durham, NC Seeds that sprout as soon as they,re ... plants need to be more careful. In the wild, a ... rainy day would risk disaster. More than just an insurance ... out that seed dormancy has long-term advantages too: Plants ... give rise to more species, finds in a team of ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Plants with dormant seeds give rise to more species 2
... may aid the quest for accurate, low-cost genomic sequencing, according ... by Stuart Lindsay and his collaborators at the Biodesign Institute ... an electron, can cross a barrier, when, according to classical ... Unraveling the DNA sequences of the human genome a ...
... N.J., March 4 BIO-key International, Inc. (OTC Bulletin ... finger-based biometric identification solutions, today announced that on or ... United States District Court for the Southern District of ... two of the Company,s investors, Longview Special Finance, Inc. ...
... Detects Faces in Motion, Matches with Watch-list ... Lithuania, March 9 Neurotechnology, a provider ... the availability of VeriLook Surveillance SDK, a ... using live video streams from high-resolution digital ...
Cached Biology News:Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 2Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 3Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 4BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 2BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 3VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Clinton will,participate as one of the main speakers at the ... in Sao Paulo, Brazil. The event is organized by the,Brazilian ... gatherings focused on biofuels in the world. , ... a second term,in six decades. After leaving the White House, ...
... - Aegera Therapeutics is pleased to announce the ... for AEG33773, a novel, orally bio-available small molecule ... neuropathy. , The Phase 2a study, entitled A ... and Efficacy of AEG33773 versus Placebo in Patients ...
... announced successful,completion of the single-day oral dosing part ... patients with its new anti-cancer drug AXL1717,an,insulin-like growth ... the closely related insulin receptor. The study is ... The results showed that a single-day,dosing of AXL1717 ...
Cached Biology Technology:President Bill Clinton to Speak at the Ethanol Summit in Brazil 2Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2
Homo sapiens olfactomedin 1, transcript variant 3...
RABBIT ANTI QUINOLINIC ACID...
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Biology Products: